Author pages are created from data sourced from our academic publisher partnerships and public sources.
- Publications
- Influence
Predicting QRS and PR interval prolongations in humans using nonclinical data
- L. Bergenholm, J. Parkinson, J. Mettetal, N. Evans, M. Chappell, T. Collins
- Medicine
- British journal of pharmacology
- 1 October 2017
Risk of cardiac conduction slowing (QRS/PR prolongations) is assessed prior to clinical trials using in vitro and in vivo studies. Understanding the quantitative translation of these studies to the… Expand
PKPD modelling of PR and QRS intervals in conscious dogs using standard safety pharmacology data.
- L. Bergenholm, T. Collins, N. Evans, M. Chappell, J. Parkinson
- Medicine
- Journal of pharmacological and toxicological…
- 1 May 2016
INTRODUCTION
Pharmacokinetic-pharmacodynamic (PKPD) modelling can improve safety assessment, but few PKPD models describing drug-induced QRS and PR prolongations have been published. This… Expand
Quantifying Drug‐Induced Bone Marrow Toxicity Using a Novel Haematopoiesis Systems Pharmacology Model
- C. Fornari, Lenka Oplustil O'Connor, +6 authors T. Collins
- Biology, Medicine
- CPT: pharmacometrics & systems pharmacology
- 20 October 2019
Haematological toxicity associated with cancer therapeutics is monitored by changes in blood cell count, and their primary effect is on proliferative progenitors in the bone marrow. Using… Expand
Understanding Hematological Toxicities Using Mathematical Modeling
- C. Fornari, Lenka Oplustil O’Connor, +4 authors T. Collins
- Medicine
- Clinical pharmacology and therapeutics
- 1 October 2018
Balancing antitumor efficacy with toxicity is a significant challenge, and drug‐induced myelosuppression is a common dose‐limiting toxicity of cancer treatments. Mathematical modeling has proven to… Expand
A tutorial on model informed approaches to cardiovascular safety with focus on cardiac repolarisation
- S. A. Cheung, J. Parkinson, +9 authors B. Hamrén
- Medicine
- Journal of Pharmacokinetics and Pharmacodynamics
- 7 May 2018
Drugs can affect the cardiovascular (CV) system either as an intended treatment or as an unwanted side effect. In both cases, drug-induced cardiotoxicities such as arrhythmia and unfavourable… Expand
Discovery and pharmacological characterization of AZD3229, a potent KIT/PDGFRα inhibitor for treatment of gastrointestinal stromal tumors
- Erica Banks, M. Grondine, +21 authors Rana Anjum
- Medicine
- Science Translational Medicine
- 29 April 2020
AZD3229 demonstrates pan-KIT/PDGFRα activity in several preclinical models and is a promising agent for the treatment of GIST. Getting the GIST of treatment Gastrointestinal stromal tumor, or GIST,… Expand
Current and future approaches to nonclinical cardiovascular safety assessment.
- T. Collins, M. G. Rolf, Amy Pointon
- Medicine
- Drug discovery today
- 21 March 2020
Our goal is to accurately predict all types of cardiovascular events in patients utilising nonclinical cardiovascular safety data. In the past two decades, cardiovascular safety science has primarily… Expand
Semi‐mechanistic modelling platform to assess cardiac contractility and haemodynamics in preclinical cardiovascular safety profiling of new molecular entities
- Raja Venkatasubramanian, T. Collins, L. Lesko, J. Mettetal, M. N. Trame
- Medicine
- British journal of pharmacology
- 25 April 2020
Cardiovascular safety is one of the most frequent causes of safety‐related attrition both preclinically and clinically. Preclinical cardiovascular safety is routinely assessed using dog telemetry… Expand
Importance of Stability Analysis When Using Nonlinear Semimechanistic Models to Describe Drug‐Induced Hematotoxicity
- C. Fornari, C. Pin, J. Yates, J. Mettetal, T. Collins
- Computer Science, Medicine
- CPT: pharmacometrics & systems pharmacology
- 26 May 2020
TLDR